ArticleArchives of toxicology2021
Genetic variants in N6-methyladenosine are associated with bladder cancer risk in the Chinese population.
Abstract read
In one paragraph
Article in Archives of toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 29 citations in OpenAlex.
- Genetic Variants in EMT-Related lncRNAs Modulate the Risk of Colorectal Cancer in the Chinese Population.Biochemical genetics · 2026Article
- m6A-SNPs identified by integrating genomic data are associated with the occurrence and prognosis of HCC.Scientific reports · 2026Article
- Cigarette smoking combines with genetic variants to regulate FOXN3 and associate with bladder cancer risk.Archives of toxicology · 2026Article
- The regulatory mechanisms and clinical translation potential of RNA-binding protein RALY in tumors.Frontiers in oncology · 2026Review
- Integrative Multiomics Analysis Identifies a Novel Gene Signature That Predicts Chemotherapy Resistance and Poor Survival in Osteosarcoma.Human mutation · 2026Article
- The Emerging Role of METTL3 in Lung Diseases.International journal of molecular sciences · 2025Review
- Dynamic Rendition of Adipose Genes Under Epigenetic Regulation: Revealing New Mechanisms of Obesity Occurrence.Current issues in molecular biology · 2025Review
- The role of CDK8 gene polymorphisms in bladder cancer susceptibility and prognosis: a study in the Chinese Han population.BMC cancer · 2025Article
- Structural Analysis of Virus Regulatory N6-Methyladenosine (m6A) Machinery of the Black Flying Fox (Genes · 2024Article
- Article
- Alternative polyadenylation-related genetic variants contribute to bladder cancer risk.Journal of biomedical research · 2023Article
- The therapeutic targets of N6-methyladenosine (m6A) modifications on tumor radioresistance.Discover oncology · 2023Review
- Review
- Genome-wide detection of m6A-associated SNPs in atrial fibrillation pathogenesis.Frontiers in cardiovascular medicine · 2023Article
- SOD2 Gene Variants (rs4880 and rs5746136) and Their Association with Breast Cancer Risk.Current issues in molecular biology · 2022Article
- The Role of mCancers · 2022Review
- N6-methyladenosine-related single-nucleotide polymorphism analyses identify oncogene RNFT2 in bladder cancer.Cancer cell international · 2022Article
- Incidence, prognostic factors and survival in bladder cancer patients: a population-based study.Translational cancer research · 2022Article
- Construction and validation of a novel prognostic model for lung squamous cell cancer based on N6-methyladenosine-related genes.World journal of surgical oncology · 2022Article
- Identification of adenylate cyclase 2 methylation in bladder cancer with implications for prognosis and immunosuppressive microenvironment.Frontiers in oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 7 institutions in 2 countries.
Hanting Liu *Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Jingjing Gu *Department of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Yu Jin *Department of Laboratory Medicine, School of Public Health, Nantong University, Nantong, China.
Qi YuanDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Gaoxiang MaDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Mulong DuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Yuqiu GeDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Chao QinDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Qiang LvDepartment of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guangbo FuDepartment of Urology, The Affiliated Huai'an First People's Hospital of Nanjing Medical University, Nanjing, China.
Meilin WangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China.
Haiyan ChuDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. chy_grape@njmu.edu.cn.
Lin YuanDepartment of Urology, Jiangsu Province Hospital of Traditional Chinese Medicine, Nanjing, China. yuanlin47@126.com.
Zhengdong ZhangDepartment of Environmental Genomics, Jiangsu Key Laboratory of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, 211166, China. drzdzhang@njmu.edu.cn.ORCID 0000-0002-6730-9251
Nanjing Medical University · CNJiangsu Province Hospital · CNMinistry of Education · KRChina Pharmaceutical University · CNHuaian First People’s Hospital · CNNanjing Traditional Chinese Medicine Hospital · CNNantong University · CN
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently N
Indexed as
Polymorphism, Single NucleotideAdenosineAgedAsian PeopleCase-Control StudiesChinaFemaleGenetic Predisposition to DiseaseGenome-Wide Association StudyHeterogeneous-Nuclear Ribonucleoprotein Group CHumansMaleMiddle AgedMolecular EpidemiologyPhenotypeRisk AssessmentAdenosineHeterogeneous-Nuclear Ribonucleoprotein Group CHNRNPC protein, humanN-methyladenosineSuperoxide DismutaseSuperoxide Dismutase 2Bladder cancerMolecular epidemiologyN6-methyladenosineSusceptibility
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.